A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia
Phase of Trial: Phase II
Latest Information Update: 11 Dec 2017
At a glance
- Drugs ACP 01 (Primary)
- Indications Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Hemostemix
- 06 Dec 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2022.
- 06 Dec 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2021.
- 01 Sep 2016 Status changed from suspended to recruiting, as per Hemostemix media release.